🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Takayuki Yoshino

National Cancer Center Hospital East

ORCID: 0000-0002-0489-4756
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 7%percentile
0.104Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Associations between early tumor shrinkage/depth of response and survival from the ARCAD database

JNCI Cancer Spectrum(2025)10.1093/jncics/pkaf042
Top 78%
0.104DataRank
Top 78%1 citations

Yuriko Takeda, Toshihiro Misumi, Tomomi Nishikawa, Masashi Wakabayashi, Kentaro Yamazaki +14 more

Papers

Driven by 10 papers — median percentile 22. Top paper: “Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer”.

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer

New England Journal of Medicine(2025)10.1056/nejmoa2501912
N/A
1.9DataRank · unranked
114 citations

Takayuki Yoshino, Lin Shen, Sara Lonardi, Eric Van Cutsem, Cathy Eng +15 more

Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database

Annals of Oncology(2020)10.1016/j.annonc.2019.12.007
N/A
1.4DataRank · unranked
34 citations

Jun Yin, Richard M. Goldberg, Levi Pederson, Norman Wolmark, Steven R. Alberts +11 more

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

Nature Medicine(2025)10.1038/s41591-024-03443-3
N/A
1.3DataRank · unranked
108 citations

Takayuki Yoshino, Eric Van Cutsem, Cathy Eng, Tae Won Kim, Harpreet Wasan +10 more

Associations between early tumor shrinkage/depth of response and survival from the ARCAD database

JNCI Cancer Spectrum(2025)10.1093/jncics/pkaf042
Top 78%
0.104DataRank
Top 78%1 citations

Yuriko Takeda, Toshihiro Misumi, Tomomi Nishikawa, Masashi Wakabayashi, Kentaro Yamazaki +14 more

A new prognostic and predictive tool for shared decision making in stage III colon cancer

European Journal of Cancer(2020)10.1016/j.ejca.2020.07.031
N/A
0DataRank · unranked
69 citations

Alberto Puccini, Qian Shi, Axel Grothey, Thierry André, Anthony F. Shields +6 more

Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1379
N/A
0DataRank · unranked
13 citations

Yoshiaki Nakamura, Rona Yaeger, Sara Lonardi, Chiara Cremolini, Élena Elez +17 more

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors

medRxiv(2022)10.1101/2022.02.17.22271120
N/A
0DataRank · unranked
1 citations

Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A. Nebhan, Ibiayi Dagogo‐Jack +24 more

Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4004
N/A
0DataRank · unranked
36 citations

Thierry André, Jeffrey A. Meyerhardt, Axel Grothey, Timothy Iveson, Takayuki Yoshino +15 more

Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4099
N/A
0DataRank · unranked
1 citations

Jesse G. Dixon, Hiral D. Parekh, Steven R. Alberts, Greg Yothers, Carmen J. Allegra +15 more

Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials

JNCI Journal of the National Cancer Institute(2021)10.1093/jnci/djab187
N/A
0DataRank · unranked
16 citations

Mohamed E. Salem, Jesse G. Dixon, Zhaohui Jin, Romain Cohen, Aimery DeGramont +16 more